Capsules (e.g., Of Gelatin, Of Chocolate, Etc.) Patents (Class 424/451)
  • Patent number: 11426566
    Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TLR agonist.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 30, 2022
    Assignee: BIORA THERAPEUTICS, INC.
    Inventors: Mitchell Lawrence Jones, Sharat Singh, Christopher Loren Wahl, Harry Stylli
  • Patent number: 11419938
    Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: August 23, 2022
    Assignee: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LLC
    Inventors: Amanda R Alley, William A Bubnis, Stephanie Shield
  • Patent number: 11406712
    Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: August 9, 2022
    Assignee: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS LLC
    Inventors: Amanda R Alley, William A Bubnis, Stephanie Shield
  • Patent number: 11401382
    Abstract: Thermoplastic polyamide particles comprising at least one polyamide and at least one polymeric ionic compound comprising imidazolium groups (imidazolium compound), the thermoplastic polyamide particles having an ellipsoidal or approximately ellipsoidal shape with the largest diameter of 1 to 100 mm, preferably 2 to 10 mm, more preferably 3 to 8 mm.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: August 2, 2022
    Assignee: BASF SE
    Inventors: Martina Schoemer, Jean-Pierre Berkan Lindner, Simon Kniesel, Juergen Wiethan
  • Patent number: 11395827
    Abstract: Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, propylene glycol and water and the weight ratio between the propylene glycol and water contained in the oil-in-water emulsion is from 1:1 to about 1:3.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: July 26, 2022
    Assignee: GALENICA AB
    Inventors: Henri Hansson, Anna Karin Morén
  • Patent number: 11383048
    Abstract: The present invention provides a device for delivering a predetermined amount of at least one substance to a body orifice of a subject; comprising: a. a container for containing said at least one substance; b. a delivery end for placement in proximity to said orifice, said delivery end being in fluid communication with said container; c. a valve mechanically connectable to said container, characterized by at least two configurations: (i) an ACTIVE CONFIGURATION in which said valve enables delivery of predetermined amount of said substance from said container to said body orifice via said delivery end; and, (ii) an INACTIVE CONFIGURATION, in which said valve prevents delivery of said predetermined amount of said substance from said container to said body orifice; d. a trigger mechanism adapted to reconfigure said valve from said INACTIVE CONFIGURATION to said ACTIVE CONFIGURATION, and vice versa; e. a fluid tight chamber.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: July 12, 2022
    Assignee: SIPNOSE LTD.
    Inventors: Daniel Shahaf, Iris Shichor
  • Patent number: 11376344
    Abstract: The present disclosure describes, among other things, a thereto-responsive hydrogel comprising a PNIPAM copolymer having adhesive properties that are temperature dependent, as well as a device for administering the hydrogel, and methods for making and using the foregoing.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: July 5, 2022
    Assignee: University of Southern California
    Inventors: John J. Whalen, III, Niki Bayat, Yi Zhang, Paulo Falabella, Mark E. Thompson, Mark S. Humayun
  • Patent number: 11359226
    Abstract: Embodiments of systems, methods, and compositions provided herein relate to hollow beads encapsulating single cells. Some embodiments include performing multiple co-assays on a single cell encapsulated within a hollow bead, including nucleic acid sequencing, preparing nucleic acid libraries, determining methylation status, identifying genomic variants, or protein analysis.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: June 14, 2022
    Assignee: ILLUMINA, INC.
    Inventors: Frank J. Steemers, Ramesh Ramji, Steven Norberg, Lena Christiansen, Dmitry K. Pokholok, Fan Zhang
  • Patent number: 11357791
    Abstract: A composition comprising kappa-carrageenan and a carrier solution, wherein the carrier solution is an isotonic solution, and methods of use thereof in the treatment of diseases or conditions of the upper airways.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: June 14, 2022
    Assignee: ENT TECHNOLOGIES PTY LTD
    Inventor: Sam Barbalatt
  • Patent number: 11351188
    Abstract: The invention provides compositions and methods to treat diabetic neuropathies. In particular the invention has discovered that, in combination with a folic compound, particular combinations of two types of additional antioxidants have complementary effects for use against diabetic neuropathies. These include antioxidants that comprise stabilizing heteroatoms and antioxidants with an extended conjugated segment, where at least one of the antioxidants that comprises a stabilizing heteroatom also has pro-oxidant effects.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: June 7, 2022
    Inventor: William H. Cross, III
  • Patent number: 11338118
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: May 24, 2022
    Assignee: RANI THERAPEUTICS, LLC
    Inventor: Mir Imran
  • Patent number: 11337926
    Abstract: A colon-targeted composition of a biological active component is disclosed, as well as formulations and preparation methods thereof. The colon-targeted composition of a biological active component includes in weight percentage: 10-99% hydroxypropyl methylcellulose, 1-60% biological active component and 0-80% auxiliary material, wherein the viscosity of hydroxypropyl methylcellulose is greater than 1,000 mPa·s. The colon-targeted composition of a biological active component has an improved colon-targeted effect and improves the bioavailability and in vivo activity of the biological active component.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: May 24, 2022
    Assignee: NANJING HEALSOUL LIFE SCIENCE AND TECHNOLOGY CO., LTD.
    Inventors: Junshou Zhang, Chaonan Sun, Hao Zhang
  • Patent number: 11318101
    Abstract: An object of the present invention is to improve the hardness of the capsule film of a hard capsule. The present invention improves the hardness of the capsule film of a hard capsule by adding a starch decomposition product, and/or at least one clay mineral selected from the group consisting of talc, bentonite, and kaolin, to a hard capsule film.
    Type: Grant
    Filed: July 4, 2017
    Date of Patent: May 3, 2022
    Assignee: QUALICAPS CO., LTD.
    Inventors: Yoshiro Osaki, Toshimitsu Usui, Makoto Aso
  • Patent number: 11311552
    Abstract: The invention relates to 6-{4-[1-(Propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, for use in treatment of CNS cancers. The invention also relates to combination treatments with irradiation and/or a chemotherapeutic agent for use in the treatment of cancer.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 26, 2022
    Assignee: Proximagen, LLC
    Inventors: Peter Richardson, Jacqueline Mary Walling, Claudio Festuccia
  • Patent number: 11311621
    Abstract: Organosilicon compound microparticles and process for their preparation It is provided a combination of an organosilicon compound and arabic gum in the form of microparticles, wherein the organo silicon has the formula (I): wherein R1 and R2 are independently selected from hydrogen and a (CrC4)alkyl group; R3 is hydroxyl; and R4 is hydroxyl or a (CrC4) alkyl group; the arabic gum is forming a polymeric matrix having interspaces, and the organosilicon compound is distributed in the interspaces of the polymeric matrix. It is also provided a process for its preparation and a composition comprising the mentioned combination.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: April 26, 2022
    Assignee: SILICIUM LABORATORIES, LLC
    Inventor: Joan Carles Hierro Pilas
  • Patent number: 11304895
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: April 19, 2022
    Assignee: RANI THERAPEUTICS, LLC
    Inventor: Mir Imran
  • Patent number: 11298372
    Abstract: The present invention provides novel compositions for suppressing or improving hair loss, and compositions for suppressing or improving graying. More specifically, it provides agents that stabilize type XVII collagen expression, preferably agents that suppress the degradation of type XVII collagen by ELANE inhibitors and such, and compositions comprising a DNA repair-promoting agent or a DNA damage-suppressing agent as an active ingredient. Advantageous suppressive effects of hair loss and graying can be obtained when a composition comprising as an active ingredient a suppressive agent of type XVII collagen degradation such as an ELANE inhibitor is administered to a mammal. For the ELANE inhibitors, suppressive agents of type XVII collagen degradation and DNA repair-promoting agents, low-molecular compounds, polypeptides, proteins, antibodies, or nucleic acid medicine such as antisense oligos or siRNAs may be used.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: April 12, 2022
    Assignee: National University Corporation Tokyo Medical and Dental University
    Inventors: Emi Nishimura, Hiroyuki Matsumura
  • Patent number: 11291613
    Abstract: Provided are coated particles and methods of their use for providing healthcare benefits. More specifically, the present invention provides amino acid and/or polymer-coated particles, or particles coated with other materials, for binding to, or otherwise associating with, surfaces of the oral cavity.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: April 5, 2022
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Robert Gambogi, Latrisha Petersen, Sherket Peterson, Andrew Glowacki, Meenakshi Patel
  • Patent number: 11285102
    Abstract: An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: March 29, 2022
    Assignee: Clexio Biosciences Ltd.
    Inventors: Avshalom Ben Menachem, Ilan Zalit
  • Patent number: 11278499
    Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 22, 2022
    Assignee: Triastek, Inc.
    Inventor: Xiaoling Li
  • Patent number: 11278506
    Abstract: A formulation for oral administration comprises an expectorant, an analgesic, and at least one additional active ingredient having a modified release providing a therapeutic effect for each of the active ingredients for up to 12 hours.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: March 22, 2022
    Assignee: RB HEALTH (US) LLC
    Inventors: Raghu Cavatur, Kevin Chen, Matthew Kaser, Hongchun Qiu, Ernest Joseph Woodhouse, Josef Borovicka, Elliot Wilkinson
  • Patent number: 11253686
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: February 22, 2022
    Assignee: RANI THERAPEUTICS, LLC
    Inventor: Mir Imran
  • Patent number: 11234935
    Abstract: The invention provides a method of inducing satiety in a subject comprising a step of orally administering a composition comprising an effective amount of a first agent capable of inducing satiety and of a second agent capable of augmenting the satiety-inducing effect of the first agent. Also disclosed are compositions for carrying out the method and a body weight management system comprising such compositions in combination with a device configured for the collection, storage and/or display of information relating to a subject's response to a predefined therapeutic regimen of orally administering the composition.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: February 1, 2022
    Assignee: PERORA GMBH
    Inventor: Dirk Vetter
  • Patent number: 11229633
    Abstract: The present invention relates to a pharmaceutical formulation which provides for extended release of an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: January 25, 2022
    Assignee: Orphazyme A/S
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Gert Mads Bolwig, Carlos Roberto Camozzi
  • Patent number: 11229684
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: January 25, 2022
    Assignee: RANI THERAPEUTICS, LLC
    Inventor: Mir Imran
  • Patent number: 11224576
    Abstract: The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: January 18, 2022
    Assignee: GRÜNENTHAL GMBH
    Inventors: Elisabeth Arkenau-Marić, Johannes Bartholomäus
  • Patent number: 11191769
    Abstract: The present disclosure provides compounds that modulate protein function, to restore protein homeostasis, and cell-cell adhesion. The disclosure provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, are provided.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: December 7, 2021
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah Fung, Frank Mercurio, Robert Sullivan
  • Patent number: 11185589
    Abstract: The present disclosure is directed to a pharmaceutical formulation intended for oral delivery of synthetic or natural poorly permeable molecules or salts/solvates thereof having a therapeutic activity. The pharmaceutical formulation can include a synthetic or natural poorly permeable molecule or salt or solvate thereof in an amount 0.01-10 wt. % of the total weight of the formulation; a lipophilic phase comprising triglycerides of fatty acids in an amount of 50-80 wt. % of the total weight of the formulation; and at least one lipophilic surfactant comprising partial esters of polyol and fatty acids in an amount of about 10-50 wt. % of the total weight of the formulation.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: November 30, 2021
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Vincent Plassat, Benoit Hilbold, Aurélia Galus, Thomas Pointeaux, Julien Meissonnier
  • Patent number: 11185516
    Abstract: The present disclosure relates to metformin glycinate and methods of using metformin glycinate for the treatment of diseases including diabetes mellitus, obesity, dyslipidemia, diseases associated with IL-10 up-regulation, and diseases or disorders associated with elevated or increased ceramide levels. Pharmaceutical formulations comprising metformin glycinate are also disclosed.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: November 30, 2021
    Assignee: Laboratorios Silanes S.A. DE C.V.
    Inventor: Jorge González-Canudas
  • Patent number: 11166963
    Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: November 9, 2021
    Assignee: THERAPEUTICSMD, INC.
    Inventors: Brian A. Bernick, Janice Louise Cacace, Peter H. R. Persicaner, Neda Irani, Julia M. Amadio, Frederick D. Sancilio
  • Patent number: 11160754
    Abstract: Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: November 2, 2021
    Assignee: CritiTech, Inc.
    Inventors: Michael Baltezor, Matthew McClorey, William Johnston, Gere S. diZerega, James Verco
  • Patent number: 11147767
    Abstract: The present invention relates to gastroretentive formulations and to processes for preparation of the same. Particularly, the invention relates to gastroretentive dosage forms comprising at least one swelling agent and at least one swelling retardant.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: October 19, 2021
    Assignee: RUBICON RESEARCH PRIVATE LIMITED
    Inventor: Pratibha Pilgaonkar
  • Patent number: 11141381
    Abstract: A composition for an enteric hard capsule by taking advantage of conventionally unknown thermal gelation characteristics of a neutralized aqueous solution of an enteric polymer, so as to obtain an enteric capsule having sufficient water and acid resistances. More specifically, the composition has hypromellose acetate succinate having a molar substitution with an acetyl group per anhydroglucose unit of 0.6 to 0.8 and a ratio of the molar substitution with an acetyl group to a molar substitution with a succinyl group per anhydroglucose unit of 2.0 to 4.0, a neutralizer, and water method produces an enteric hard capsule having the steps of: immersing a core pin heated at 50 to 80° C. in the composition, taking the immersed core pin out of the composition, and drying a gel layer of the hypromellose acetate succinate formed on the taken-out core pin.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: October 12, 2021
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventor: Naosuke Maruyama
  • Patent number: 11076931
    Abstract: A capsule for detection of gastrointestinal motility and a method for preparing such a capsule is provided. The capsule comprises a capsule enclosure and a preset quantity of radiopaque markers filled in the capsule. The radiopaque markers further comprise a solid X-ray contrast agent, a medical plastic with a density of at most at 1.4 g/cm3 and an auxiliary agent.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 3, 2021
    Assignee: Ankon Medical Technologies (Shanghai) Co., LTD.
    Inventors: Xiaodong Duan, Hongjiao Song, Shaobang Zhang
  • Patent number: 11058661
    Abstract: In various embodiments, the present disclosure provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof having triglyceride levels of about 200 mg/dL to about 499 mg/dL, and hsCRP levels ?2.0 mg/L.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: July 13, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Sephy Philip
  • Patent number: 11046810
    Abstract: A novel method for the preparation of biodegradable polymers is disclosed. The method produces polymers of high molecular weight and particularly allows for stirring throughout the polymerization reaction.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: June 29, 2021
    Assignee: PHARMATHEN S.A.
    Inventors: V. Theocharis Koftis, Efstratios Neokosmidis, Konstantina Karidi, Anastasia-Aikaterini Varvogli
  • Patent number: 11039637
    Abstract: A composition comprising probiotic bacteria, the composition comprising: (a) a core composition containing the probiotic bacteria and a stabilizer, wherein the total amount of probiotics in the mixture is from about 10% to about 90% by weight of the core composition; (b) an innermost coating layer, layered on said core composition, comprising at least one hydrophobic solid fat or fatty acid having a melting point lower than 60° C.; (c) an intermediate coating layer layered on said innermost coating layer, which when present in an aqueous solution in the amount of 0.1% weight/weight over the weight of the solution, has a surface tension lower than 60 mN/m, when measured at 25° C.; and (d) an outer coating layer, layered on said intermediate coating layer; wherein the composition is in the form of particles; food products containing the composition and methods of preparation thereof.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: June 22, 2021
    Assignee: DeGama Berrier Ltd.
    Inventor: Adel Penhasi
  • Patent number: 11033504
    Abstract: The invention relates to a film-forming composition comprising a fluidised hydroxypropyl starch and sorbitol, and to a film-coating method using said composition. The invention further relates to film-coated solid forms comprising a fluidised hydroxypropyl starch and sorbitol in the coating.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: June 15, 2021
    Assignee: ROQUETTE FRERES
    Inventors: Xavier Parissaux, Gregory Le Bihan, Sebastien Croquet
  • Patent number: 11033509
    Abstract: The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: June 15, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Shyam B. Karki, Peter Zawaneh, Cheuk-Yui Leung, Kalyan Vasudevan, Yiqing Lin, Jin Xu, Andrea Trementozzi, Ivan Nestorov
  • Patent number: 11026908
    Abstract: The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.
    Type: Grant
    Filed: July 16, 2017
    Date of Patent: June 8, 2021
    Assignee: MAPI PHARMA LTD.
    Inventors: Yoram Sela, Shai Rubnov
  • Patent number: 11013713
    Abstract: Embodiments of the invention relate generally to increasing adult height in individuals with no light perception (NLP).
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 25, 2021
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
  • Patent number: 10993915
    Abstract: The invention relates to self-assembling microparticles comprising a solid matrix and probiotic bacteria, wherein the solid matrix comprises soybean protein and a divalent or trivalent metal, and wherein the probiotic bacteria are distributed throughout the solid matrix; said matrix protects said probiotic bacteria during processing, storage, as well as during transit through the gastrointestinal tract, thus prolonging their lifetime and facilitating release into the intestine and improving their probiotic effect. The present invention also relates to the method for obtaining the self-assembling microparticles and to the products and compositions incorporating them.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: May 4, 2021
    Assignees: UNIVERSIDAD DE NAVARRA, CENTRO NACIONAL DE TECNOLOGIA Y SEGURIDAD ALIMENTARIA
    Inventors: Carolina González Ferrero, Carlos Javier González Navarro, Juan Manuel Irache Garreta, Beatriz Marín Calvo, Ana Romo Hualde, Raquel Virto Resano
  • Patent number: 10980266
    Abstract: Shown herein is a nutritional supplement containing apple cider vinegar (ACV), including compositions, formulations, and combinations of ingredients in the ACV nutritional supplement, as well as processes for manufacturing these supplements. The nutritional supplement can include ACV, a gelling agent such as pectin or gelatin, an oligosaccharide, a disaccharide, and water.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 20, 2021
    Assignee: Goli Nutrition Inc.
    Inventors: Michael Bitensky, Nicol Korner-Bitensky, Olivia Joan Dahm, Roger Arthur Tyre, Sharon Hoffman, Deepak Agarwal
  • Patent number: 10980828
    Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 20, 2021
    Assignee: L & F Research LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10980265
    Abstract: Shown herein is a nutritional supplement containing apple cider vinegar (ACV), including compositions, formulations, and combinations of ingredients in the ACV nutritional supplement, as well as processes for manufacturing these supplements. The nutritional supplement can include ACV, a gelling agent such as pectin or gelatin, an oligosaccharide, a disaccharide, and water.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 20, 2021
    Assignee: Goli Nutrition Inc.
    Inventors: Michael Bitensky, Nicol Korner-Bitensky, Olivia Joan Dahm, Roger Arthur Tyre, Sharon Hoffman, Deepak Agarwal
  • Patent number: 10967021
    Abstract: The present invention provides a new use or method of use of a thylakoid extract, for oral route of administration, and a composition comprising the thylakoid extract in adjunction with an acceptable carrier for oral administration. Besides the pharmaceutical use, the thylakoid extract enters the composition of food or food supplements, or medication for its innocuity and its capacity to provide a diet enriched in anti-oxidants and anti-inflammatory compounds. Therefore, in accordance with the present invention is provided the use of athylakoid extract in the making of an oral composition for treating preventing a disease or disorder involving the formation of reactive oxygen species or inflammation. Also is provided a method for treating or preventing a disease or disorder involving the formation of reactive oxygen species inflammation in an individual, which comprises the step of orality administering an effective dose of a thylakoid extact.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: April 6, 2021
    Assignee: GROUPE SANTÉ DEVONIAN
    Inventors: Marc Purcell, Réjean Drouin
  • Patent number: 10966907
    Abstract: Provided is a die roll for manufacturing softgels, a softgel, and methods for producing a softgel. The die roll includes a die roll surface and a pocket defined therein. The pocket includes a floor, an interior sidewall surface, a chamfer, and an exterior sidewall surface. The floor is recessed relative to the die roll surface and the interior sidewall surface is connected to the floor and extends above the die roll surface to the chamfer. The pocket also includes a landing surface that is elevated from the die role surface and connects the chamfer to the exterior sidewall surface of the pocket. The landing surface includes a taper (such that the landing surface tapers inwardly towards the pocket floor) and a radius (such that the landing surface is not flat). Also provided is a softgel having a trailing edge thickness that is at least about 40% the thickness of the softgel wall thickness.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: April 6, 2021
    Assignee: BARLEAN'S ORGANIC OILS, LLC
    Inventor: John Puckett
  • Patent number: 10959957
    Abstract: The disclosed are shelf-stable beta-hydroxyisovaleric acid containing soft gel compositions and methods for making such compositions. In certain aspects, disclosed compositions comprise a plant-based capsule shell and a liquid formulation comprising beta-hydroxyisovaleric acid and at least one excipient, wherein the soft gel capsule is shelf-stable. In certain aspects, the excipient is selected from selected from choline salt, betaine, phosphatidylcholine, alpha-glycerophosphocholine, carnitine, adenosine 5?-triphosphate, or a combination thereof.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: March 30, 2021
    Assignee: TSI Group Ltd.
    Inventors: Martin Purpura, Ralf Jager, Jie Gu, Xiong Zheng, Iingwei Dai, Yaohua Zhang
  • Patent number: 10940118
    Abstract: The present disclosure provides methods and compositions related to nanoparticles comprising an encapsulated hydrophobic drug. The methods described herein provide nanoparticles having a small size and a narrow size distribution.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: March 9, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Ying Liu, Zaijie Wang
  • Patent number: 10918595
    Abstract: A process for the preparation of an oral disintegrating tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Manabu Nakatani, Yohei Kawabata, Takeshi Sawada, Hiroshi Takasaki